FRCA Notes


Diabetes Mellitus

Curriculum

The curriculum asks for knowledge of management of patients with endocrine abnormalities, including diabetes mellitus.

Examiner feedback

A question on the complications of diabetes & oral hypoglycaemic drugs (September 2019) saw marks lost because "very few candidates were aware of the AAGBI guidelines on blood glucose monitoring".

A CRQ (september 2023) on newer diabetic medications and guidelines saw poor quality answers on the choice of fluid to accompany an insulin infusion.

Resources


  • Diabetes mellitus is a group of multisystem disorders characterised by hyperglycaemia, due to abnormalities of insulin secretion, insulin resistance or both (see diabetes physiology)
    • Affects ~8% of UK adults, of whom over 90% have type 2 diabetes
    • Patients with diabetes are up to 50% more likely to be referred for surgery, and up to 80% of cardiac surgical patients may have diabetes
    • Up to 40% of patients on general wards have diabetes or hyperglycaemia

  • Diabetes is associated with increased peri-operative harm, including longer hospital stay, surgical site and systemic infection, ICU admission, myocardial infarction and death
  • Most preventable inpatient harms are caused by hospital-acquired DKA, hypoglycaemia and insulin prescribing errors

  • The main anaesthetic concerns are:
    • The long-term complications of diabetes
    • Peri-operative management of diabetic medicines, including insulin
    • Peri-operative control of blood glucose and ketones

Types 1 and 2

  • Type 1: absolute insulin deficiency due to autoimmune pancreatic β-cell destruction; requires insulin and is prone to ketoacidosis
  • Type 2: insulin resistance with relative insulin deficiency, with genetic and environmental components; often coexists with the metabolic syndrome

Other types

  • Monogenic defects of β-cell function or insulin action e.g. MODY, neonatal diabetes
  • Diseases of the exocrine pancreas:
  • Endocrinopathies: Cushing's, acromegaly, phaeochromocytoma, glucagonoma
  • Drug-induced: glucocorticoids, thiazide diuretics, β-blockers, post-transplant immunosuppression
  • Gestational diabetes
  • Latent autoimmune diabetes in adults (LADA)

  • Based on elevated plasma glucose or HbA1c, with or without symptoms of hyperglycaemia (polyuria, polydipsia, fatigue, weight loss)
  1. Symptoms of hyperglycaemia and random plasma glucose ≥11.1mmol/L, or
  2. Fasting (8hrs) plasma glucose ≥7.0mmol/L, or
  3. Oral glucose tolerance test: plasma glucose ≥11.1mmol/L 2hrs after a 75g glucose load, or
  4. HbA1c ≥48mmol/mol (6.5%)
  • In the absence of symptoms, an abnormal result should be repeated to confirm the diagnosis

Non-diabetic hyperglycaemia ('pre-diabetes')

  • HbA1c 42-47mmol/mol
  • Impaired fasting glucose: fasting plasma glucose 6.1-6.9mmol/L
  • Impaired glucose tolerance: 2hr plasma glucose 7.8-11.0mmol/L after a 75g glucose load
  • These patients are at risk of developing diabetes and cardiovascular disease and should receive lifestyle advice and monitoring

  • Seen in surgical patients with dysglycaemia whether or not they have diabetes, across a range of specialties (BJA, 2022)
Complications of peri-operative dysglycaemia
↑ surgical site infection (2x)
Nosocomial infection e.g. UTI (3x) or LRTI (2.5x)
Acute kidney injury (2x)
Acute coronary syndromes (2x)
Acute cerebrovascular events
Pressure injuries and delayed wound healing
Hospital-acquired DKA and HHS
↑ length of stay and mortality (hyper- or hypoglycaemia)


Acute

  • Hyperglycaemia
  • Diabetic ketoacidosis, including euglycaemic DKA with SGLT2 inhibitors
  • Hyperosmolar hyperglycaemic state (HHS)
  • Hypoglycaemia, typically iatrogenic from insulin or sulphonylureas

Chronic: macrovascular

Chronic: microvascular

  • Nephropathy: microalbuminuria, glomerulosclerosis, chronic kidney disease
  • Neuropathy: peripheral or autonomic
  • Retinopathy
  • Stiff joint syndrome
    • Glycosylation of collagen at the temporomandibular and atlanto-occipital joints
    • Associated with a higher incidence of difficult intubation; look for the 'prayer sign'
  • General increased risk of infection

Autonomic neuropathy

  • Occurs in up to 40% of type 1 and 20% of type 2 diabetes
  • Features include:
    • Postural hypotension and cardiovascular instability under anaesthesia
    • Resting tachycardia and loss of heart rate variability with respiration
    • Absent blood pressure overshoot in phase 4 of the Valsalva manoeuvre
    • Gastroparesis and reduced lower oesophageal sphincter tone, increasing aspiration risk
    • Impaired thermoregulation
    • Bladder dysfunction and erectile dysfunction
    • Hypoglycaemic unawareness

Peri-operative management of the patient with diabetes


History and examination

  • Type and duration of diabetes, usual management and who supports it (self, GP, diabetes team)
  • Glycaemic control: HbA1c, home or continuous glucose monitoring data, frequency of hypoglycaemia and DKA
  • Use of wearable technology (continuous glucose monitors, insulin pumps, hybrid closed-loop systems)
  • Presence and severity of end-organ complications, particularly cardiovascular, renal and autonomic
  • Full drug history, including non-diabetic medicines
  • Airway assessment for stiff joint syndrome

Investigations

  • HbA1c within the last 3 months, included on the GP referral
  • U&E for nephropathy; FBC
  • Resting ECG; consider echocardiography or functional testing if concerns over cardiac disease
  • Lying and standing blood pressure if autonomic neuropathy suspected
  • Capillary blood glucose (CBG) and ketones on admission and before induction

Risk assessment and optimisation

  • The ideal HbA1c is ≤48mmol/mol as higher values are associated with worse surgical outcomes
  • If HbA1c >69mmol/mol, use clinical judgement about proceeding with elective surgery or referring back for optimisation
    • Overly aggressive optimisation in frail or comorbid patients can cause harm
    • Peri-operative diabetes specialist teams reduce complications and length of stay

  • Every patient should have a documented, individualised peri-operative care plan, including management of out-of-range glucose
  • Schedule patients first or early on the list to minimise fasting
  • No patient should be excluded from day surgery purely because they have diabetes
  • Routine carbohydrate loading is not recommended, given possible gastroparesis, inability to mount an insulin response (type 1) and the risk of hyperglycaemia
  • Patients who will need a VRII should be identified so it can be started on admission

Drug management: non-insulin medicines

  • Combination products should be prescribed as separate components so each can be managed individually

Drug class Day before surgery Day of surgery
Acarbose and meglitinides Take as normal Morning surgery: omit morning dose if not eating
Afternoon surgery: give morning dose if eating breakfast
Metformin Take as normal Once or twice daily: take as normal
Three times daily: omit lunchtime dose
Omit if eGFR <60 and contrast planned
Sulphonylureas Take as normal Morning surgery: omit morning dose (if twice daily, take evening dose if eating)
Afternoon surgery: omit all doses
Pioglitazone Take as normal Take as normal
DPP-4 inhibitors Take as normal Take as normal
GLP-1 receptor agonists Take as normal Take as normal, with an individual risk assessment for retained gastric contents
SGLT2 inhibitors Omit Omit; measure ketones daily until eating and drinking

Drug management: insulin

  • Patients with insulin-treated diabetes must always have an appropriate insulin regimen prescribed and administered
  • If no more than one meal will be missed, modify the usual subcutaneous regimen rather than starting a VRII
  • Never omit basal insulin in type 1 diabetes

Insulin regimen Day before surgery Day of surgery
Once daily long-acting, evening
(e.g. glargine, detemir, degludec)
Give 80% of usual dose Check CBG on admission
Once daily long-acting, morning No change Give 80% of usual dose
Twice daily long-acting Give 80% of evening dose Give 80% of morning dose; evening dose unchanged
Twice daily premixed
(e.g. NovoMix 30, Humulin M3)
No change Halve the morning dose; evening dose unchanged
Basal-bolus No change Basal as above; omit rapid-acting insulin with missed meals
Continuous subcutaneous insulin infusion (pump) No change Continue only if agreed criteria met (see below); otherwise convert to VRII

Variable rate intravenous insulin infusion (VRII)

  • Only consider a VRII if there is metabolic derangement or more than one meal will be missed
    • Avoiding unnecessary VRIIs reduces hypoglycaemia, hyponatraemia and prescribing errors
  • Continue long-acting basal insulin at 80% of the usual dose alongside the VRII
  • Stop short-acting, intermediate and premixed insulins while the VRII runs
  • A glucose-containing substrate fluid must run concurrently and one should never stop the substrate while insulin is running
    • This is typically 0.18% saline + 4% dextrose ± KCl 20-40mmol/L at a rate of ~30ml/kg/day
    • No single fluid meets all daily fluid/electrolyte requirements so check U&E and fluid balance daily as hyponatraemia is a risk
  • Check CBG hourly

Wearable technology

  • Agree a multidisciplinary care plan before surgery for patients with continuous glucose monitors, pumps or hybrid closed-loop systems
  • Insulin pumps can be continued if:
    • Only one meal will be missed and there is no metabolic derangement
    • The patient can self-manage and agrees, keeping CBG 6-10mmol/L
    • The pump can be sited away from the surgical field and not between the diathermy plate and the operative site
    • A Teflon (not steel) cannula is used, and CBG can be checked every 30-60mins
  • If insulin delivery is interrupted, start an alternative source of insulin immediately
  • All wearable devices must be removed for MRI

Targets

  • CBG 6-10mmol/L if treated with insulin, sulphonylureas or meglitinides
  • CBG 4-10mmol/L if diet-controlled or on other medicines
  • Better glycaemic control is associated with reduced peri-operative morbidity and mortality
  • The surgical stress response stimulates gluconeogenesis and insulin resistance, often increasing insulin requirements (see diabetes physiology)

Monitoring

  • Perform regular point-of-care CBG measurement; hourly if on a VRII
  • Continuous glucose monitors cannot be relied on under anaesthesia so confirm with blood sampling

Managing out-of-range glucose

  • Hypoglycaemia:
    • Anaesthesia masks symptoms, so intervene if CBG <6mmol/L in patients on glucose-lowering medicines to prevent progression to <4mmol/L
    • Give intravenous glucose e.g. 75-100ml of 20% glucose, and recheck CBG after 10-15mins

  • Hyperglycaemia (CBG >10mmol/L):
    • Measure capillary ketones if two or more consecutive readings are >13mmol/L, or the patient is unwell
    • Ketones ≥3mmol/L with acidosis indicate DKA, which should be treated with a FRII
    • Otherwise give a correction dose of rapid-acting insulin according to local protocol; the expected fall per unit can be estimated as 100 ÷ total daily dose (mmol/L)
    • Avoid repeating subcutaneous doses within 2-3hrs ('insulin stacking')

Anaesthetic technique

  • Choose anaesthesia and analgesia that enable early drinking, eating and resumption of usual diabetes medicines
  • Minimise PONV: consider awake techniques, TIVA, avoiding nitrous oxide and multimodal anti-emesis
  • Consider regional anaesthesia, weighing benefits (airway, aspiration, PONV, early DrEaMing) against risks of nerve injury, prolonged block and infection

Dexamethasone

  • Previously considered a relative contraindication, but there is increasing evidence that it reduces opioid requirements, improves pain and aids recovery
  • A single dose raises glucose modestly; higher doses (>8mg) raise it more
  • The PADDI trial (2021) found 8mg did not increase surgical site infection, including in patients with diabetes
  • Monitor CBG for several hours afterwards

Airway and aspiration

  • Anticipate a more difficult airway if stiff joint syndrome is present
  • Aspiration risk is increased by gastroparesis, GLP-1 receptor agonists and coexisting obesity
    • Gastric emptying is slower in diabetes, although this does not necessarily increase gastric volume or aspiration (BJA, 2021)
    • Consider antacids, prokinetics, gastric ultrasound and a lower threshold for RSI

Other considerations

  • Autonomic neuropathy predisposes to haemodynamic instability on induction and hypothermia
  • Ensure appropriate antibiotic prophylaxis
  • Avoid nephrotoxins in nephropathy
  • Careful positioning and pressure-area care, particularly with neuropathy

Post-anaesthetic care unit

  • Check CBG regularly, e.g. 1-2 hourly
  • Recovery staff should have immediate access to glucose and ketone meters, rapid-acting insulin and treatment for hypoglycaemia
  • Never disconnect a VRII during transfer
  • Ensure a documented handover including oral intake, the ongoing need for a VRII, restarting usual medicines and when to contact the diabetes team

Stopping the VRII

  • In type 1 or insulin-requiring diabetes, only stop the VRII once:
    • Subcutaneous basal insulin has been given
    • CBG is <10mmol/L
    • Ketones are <0.6mmol/L
  • Ideally transition with a meal, overlapping the infusion with the first subcutaneous rapid-acting dose by 30-60mins

Ward care

  • Promote early drinking, eating and mobilisation (DrEaMing)
  • Return the patient to self-management of their usual regimen as soon as possible
  • Measure ketones daily in patients taking SGLT2 inhibitors until eating and drinking normally
  • Measure ketones and lactate if CBG >13mmol/L
  • Rescue medicines for hypo- and hyperglycaemia should be pre-prescribed
  • Remind patients of sick day rules on discharge

  • Intercurrent illness, unpredictable fasting, disrupted medicines and the stress response increase the risk of dysglycaemia, DKA or HHS

  • Expedited surgery on a scheduled list (e.g. hand trauma) can be managed as an elective case if there is no metabolic derangement
  • Prioritise patients with diabetes on the emergency list to minimise fasting
  • Only start a VRII if there is metabolic derangement or more than one meal will be missed
  • Measure ketones and lactate if CBG >13mmol/L

  • Diabetic medicines:
    • Withhold SGLT2 inhibitors on admission and monitor ketones
    • Omit metformin if there is renal derangement or intravenous contrast is planned

  • Patients with DKA or HHS should be managed with a FRII, and surgery deferred unless immediately life, limb or organ-saving